Literature DB >> 2583876

Differential effect of type I and type II diabetes mellitus on serum ampicillin levels.

C Adithan1, G Sriram, R P Swaminathan, C H Shashindran, J S Bapna, M Krishnan, S Chandrasekar.   

Abstract

Ampicillin elimination was studied in 10 poorly controlled, 6 well controlled type I and 14 poorly controlled type II diabetic patients. Two groups of age-matched healthy volunteers served as controls. After oral administration of ampicillin (500 mg), the poorly controlled type I diabetics had significantly lower serum concentration of the drug when compared to their corresponding healthy controls. The elimination half-life (t1/2) remained unaltered. Their creatinine clearance rate and urinary excretion of the drug were significantly reduced. There was no difference in these parameters between well controlled diabetics and healthy volunteers. The bioavailability data calculated from the urinary recovery of the drug, after oral and i.v. administration, suggested reduced oral absorption in poorly controlled type I diabetic patients. Ampicillin kinetics data of poorly controlled type II diabetic patients were not significantly different from that of the control group. Serum ampicillin levels and urinary excretion of the drug were similar in these groups. It is concluded that serum ampicillin level may be lower in poorly controlled type I diabetics which may be due to reduced absorption of the orally administered drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583876

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

Review 1.  The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.

Authors:  P R Gwilt; R R Nahhas; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Drug administration in patients with diabetes mellitus. Safety considerations.

Authors:  R E Gilbert; M E Cooper; H Krum
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

3.  Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.

Authors:  Sarah C Mann; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Austin Saderup; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-01       Impact factor: 3.771

4.  Diabetes downregulates peptide transporter 1 in the rat jejunum: possible involvement of cholate-induced FXR activation.

Authors:  Li-Min Liang; Jun-Jie Zhou; Feng Xu; Pei-Hua Liu; Lan Qin; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 7.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.